**Integrated genomic characterization of endometrial carcinoma**

The Cancer Genome Atlas Research Network

We performed an integrated genomic, transcriptomic and proteomic characterization of 373 endometrial carcinomas using array- and sequencing-based technologies. Uterine serous tumours and ~25% of high-grade endometrioid tumours had extensive copy number alterations, few DNA methylation changes, low oestrogen receptor/progesterone receptor levels, and frequent TP53 mutations. Most endometrioid tumours had few copy number alterations or TP53 mutations, but frequent mutations in *PTEN*, *CTNNB1*, *PIK3CA*, *ARID1A* and *KRAS* and novel mutations in the SWI/SNF chromatin remodelling complex gene *ARID5B*. A subset of endometrioid tumours that we identified had a markedly increased transversion mutation frequency and newly identified hotspot mutations in *POLE*. Our results classified endometrial cancers into four categories: *POLE* ultramutated, microsatellite instability hypermutated, copy-number low, and copy-number high. Uterine serous carcinomas share genomic features with ovarian serous and basal-like breast carcinomas. We demonstrated that the genomic features of endometrial carcinomas permit a reclassification that may affect post-surgical adjuvant treatment for women with aggressive tumours.

Endometrial cancer arises from the lining of the uterus. It is the fourth most common malignancy among women in the United States, with an estimated 49,500 new cases and 8,200 deaths in 2013 (ref. 1). Most patients present with low-grade, early-stage disease. The majority of patients with more aggressive, high-grade tumours who have disease spread beyond the uterus will progress within 1 year (refs 2, 3). Endometrial cancers have been broadly classified into two groups4. Type I endometrioid tumours are linked to oestrogen excess, obesity, hormone-receptor positivity, and favourable prognosis compared with type II, primarily serous, tumours that are more common in older, non-obese women and have a worse outcome. Early-stage endometrioid cancers are often treated with adjuvant radiotherapy, whereas serous tumours are treated with chemotherapy, similar to advanced-stage cancers of either histological subtype. Therefore, proper subtype classification is crucial for selecting appropriate adjuvant therapy.

Several previous reports suggest that *PTEN* mutations occur early in the neoplastic process of type I tumours and co-exist frequently with other mutations in the phosphatidylinositol-3-OH kinase (PI(3)K)/AKT pathway5,6. Other commonly mutated genes in type I tumours include *FGFR2*, *ARID1A*, *CTNNB1*, *PIK3CA*, *PIK3R1* and *KRAS*7-9. Microsatellite instability (MSI) is found in approximately one-third of type I endometrioid tumours, but is infrequent in type II tumours10. *TP53*, *PIK3CA* and *PPP2R1A* mutations are frequent in type II tumours11,12. Most of these studies have been limited to DNA sequencing only with samples of heterogeneous histological subtypes and tumour grades. We present a comprehensive, multiplatform analysis of 373 endometrial carcinomas including low-grade endometrioid, high-grade endometrioid, and serous carcinomas. This integrated analysis provides key molecular insights into tumour classification, which may have a direct effect on treatment recommendations for patients, and provides opportunities for genome-guided clinical trials and drug development.

**Results**

Tumour samples and corresponding germline DNA were collected from 373 patients, including 307 endometrioid and 66 serous (53) or mixed histology (13) cases. Local Institutional Review Boards approved all tissue acquisition. The clinical and pathological characteristics of the samples generally reflect a cross-section of individuals with recurrent endometrial cancer2,3 (Supplementary Table 1.1). The median follow-up of the cohort was 32 months (range, 1–195 months); 21% of the patients have recurred, and 11% have died. Comprehensive molecular analyses were performed at independent centres using six genomic or proteomic platforms (Supplementary Table 1.2). MSI testing performed on all samples using seven repeat loci (Supplementary Table 1.3) found MSI in 40% of endometrioid tumours and 2% of serous tumours.

**Somatic copy number alterations**

Somatic copy number alterations (SCNAs) were assessed in 363 endometrial carcinomas. Unsupervised hierarchical clustering grouped the tumours into four clusters (Fig. 1a). The first three copy-number clusters were composed almost exclusively (97%) of endometrioid tumours without significant differences in tumour grades. Cluster 1 tumours were nearly devoid of broad SCNAs, averaging less than 0.5% genome alteration, with no significant recurrent events. Cluster 1 tumours also had significantly increased non-synonymous mutation rates compared to all others (median 7.2 × 10⁻⁶ versus 1.7 × 10⁻⁶ mutations per megabase (Mb), *P* = 0.001). Copy-number clusters 2 and 3 consisted mainly of endometrioid tumours, distinguished by more frequent 1q amplification in cluster 3 than cluster 2 (100% of cluster 3 tumours versus 33% of cluster 2 tumours) and worse progression-free survival (*P* = 0.003, log-rank versus clusters 1 and 2; Fig. 1b).

Most of the serous (50 out of 53; 94%) and mixed histology (8 out of 13; 62%) tumours clustered with 36 (12%) of the 289 endometrioid tumours versus 33% of cluster 2 tumours) and worse progression-free survival (*P* = 0.003, log-rank versus clusters 1 and 2; Fig. 1b). Most of the serous (50 out of 53; 94%) and mixed histology (8 out of 13; 62%) tumours clustered with 36 (12%) of the 289 endometrioid tumours including 24% of grade 3 and 5% of grade 1 or 2, into copy-number cluster 4; a single group characterized by a very high degree of SCNAs (Supplementary Fig. 2.1; focal SCNAs with false discovery rate (FDR) < 0.15, and Supplementary Data 2.1). Cluster 4 tumours were characterized by significantly recurrent previously reported focal amplifications of the oncogenes *MYC* (8q24.12), *ERBB2* (17q12) and *CCNE1* (19q12)13, and by SCNAs previously unreported in endometrial cancers including those containing *FGFR3* (4p16.3) and *SOX17* (8q11.23). Cluster 4 tumours also had frequent *TP53* mutations (90%),

*List of participants and their affiliations appear at the end of the paper.*
identified hotspot mutations in **POLE** at Pro286Arg and Val411Leu present in 13 (76%) of the 17 ultramutated samples. Significantly mutated genes (SMGs) identified at low FDRs (Q in this subset included **PTEN** (94%, Q = 0), **PIK3R1** (65%, Q = 8.3 \times 10^{-7}), **PIK3CA** (71%, Q = 9.1 \times 10^{-4}, **FBXW7** (82%, Q = 1.4 \times 10^{-4}), **KRAS** (53%, Q = 9.2 \times 10^{-4}) and **POLE** (100%, Q = 4.2 \times 10^{-5}). Mutation rates in **POLE** mutant endometrial and previously reported ultramutated colorectal tumours exceeded those found in any other lineage including lung cancer and melanoma. Germline susceptibility variants have been reported in **POLE** (Leu424Val) and **POLD1** (Ser478Asn), but were not found in our endometrial normal exome-seq reads.

The **MSI** endometrioid tumours had a mutation frequency approximately tenfold greater than **MSS** endometrioid tumours, few **SCNAs**, frame shift deletions in **RPL22**, frequent non-synonymous **KRAS** mutations, and few mutations in **FBXW7**, **CTNNB1**, **PPP2R1A** and **TP53**. The **MSS**, copy-number low, endometrioid tumours had an unusually high frequency of **CTNNB1** mutations (52%); the only gene with a higher mutation frequency than the **MSI** samples. The copy-number high group contained all of the remaining serous cases and one-quarter of the grade 3 endometrioid cases. Most of these tumours had **TP53** mutations and a high frequency of **FBXW7** (22%, Q = 0) and **PPP2R1A** (22%, Q = 1.7 \times 10^{-16}) mutations, previously reported as common in uterine serous but not endometrioid carcinomas. Thus, a subset of high-grade endometrioid tumours had similar **SCNAs** and mutation spectra as uterine serous carcinomas, suggesting that these patients might benefit from treatment approaches that parallel those for serous tumours.

There were 48 genes with differential mutation frequencies across the four groups (Fig. 2d and Supplementary Data 3.1). **ARID5B**, a member of the same AT-rich interaction domain (ARID) family as **ARID1A**, was more frequently mutated in **MSI** (23.1%) than in either **MSS** endometrioid (5.6%) or high **SCNA** serous tumours (0%), a novel finding for endometrial cancer. Frameshifting **RPL22** indels near a homopolymer at Lys 15 were almost exclusively found in the **MSI** group (36.9%). The **TP53** mutation frequency (>90%) in serous tumours differentiated them from the endometrioid subtypes (11.4%). However, many (10 out of 20; 50%) endometrioid tumours with a non-silent **TP53** mutation also had non-silent mutations in **PTEN**, compared to only 1 out of 39 (2.6%) serous tumours with non-silent **TP53** mutations. Although **TP53** mutations are not restricted to serous tumours, the co-existing **PTEN** mutations in the endometrioid cases suggest a distinct tumorigenic mechanism.

**Exome sequence analysis**

We sequenced the exomes of 248 tumour/normal pairs. On the basis of a combination of somatic nucleotide substitutions, **MSI** and **SCNAs**, the endometrial tumours were classified into four groups (Fig. 2a, b): (1) an ultramutated group with unusually high mutation rates (232 \times 10^{-6} mutations per Mb) and a unique nucleotide change spectrum; (2) a hypermutated group (18 \times 10^{-6} mutations per Mb) of **MSI** tumours, most with **MLH1** promoter methylation; (3) a group with lower mutation frequency (2.9 \times 10^{-6} mutations per Mb) and most of the microsatellite stable (MSS) endometrioid cancers; and (4) a group that consists primarily of serous-like cancers with extensive **SCNA** (copy-number cluster 4) and a low mutation rate (2.3 \times 10^{-6} mutations per Mb). The ultramutated group consisted of 17 (7%) tumours exemplified by an increased C→A transversion frequency, all with mutations in the exonuclease domain of **POLE**, and an improved progression-free survival (Fig. 2a, c). **POLE** is a catalytic subunit of DNA polymerase epsilon involved in nuclear DNA replication and repair. We

![Figure 1](image1.png)

**Figure 1** | **SCNAs in endometrial carcinomas.** a. Tumours were hierarchically clustered into four groups based on **SCNAs**. The heat map shows **SCNAs** in each tumour (horizontal axis) plotted by chromosomal location (vertical axis). Chr., chromosome. b. Kaplan–Meier curves of progression-free survival for each copy-number cluster.

little **MSI** (6%), and fewer **PTEN** mutations (11%) than other endometrioid tumours (84%). Overall, these findings suggest that a subset of endometrial tumours contain distinct patterns of **SCNAs** and mutations that do not correlate with traditional tumour histology or grade.

As expected, tumours in the ‘serous-like’ cluster (cluster 4) had significantly worse progression-free survival than tumours in the endometrioid cluster groups (P = 0.003, log-rank, Fig. 1b). Potential therapeutically relevant **SCNAs** included the cluster 2 15q26.2 focal amplification, which contained **IGF1R**; and cluster 4 amplifications of **ERBB2**, **FGFR1** and **FGFR3**, and **LRP1B** deletion, which was recently associated with resistance to liposomal doxorubicin in serous ovarian cancer.
in the MSI cluster was decreased MLH1 mRNA expression, probably due to its promoter methylation. Increased progesterone receptor (PGR) expression was noted in the copy-number low cluster, suggesting responsiveness to hormonal therapy. The copy-number high cluster, which included most of the serous and serous-like endometrioid tumours, exhibited the greatest transcriptional activity exemplified by increased transcriptional activity exemplified by increased expression was noted in the copy-number low cluster, suggesting responsiveness to hormonal therapy. The copy-number high cluster, which included most of the serous and serous-like endometrioid tumours, exhibited the greatest transcriptional activity exemplified by increased transcriptional activity exemplified by increased cell cycle deregulation (for example, CCNE1, PIK3CA, MYC and CDKN2A) and TP53 mutation (Supplementary Figs. 4.2 and 4.3). This is consistent with reports that increased CDKN2A can distinguish serous from endometrioid carcinomas. Approximately 85% of cases in the copy-number high cluster shared membership with the ‘mitotic’ mRNA subtype.

Supervised clustering of the reverse phase protein array (RPPA) expression data was consistent with loss of function for many of the mutated genes (Fig. 3b). TP53 was frequently mutated in the copy-number high group \( (P = 2.5 \times 10^{-27}) \) and its protein expression was also decreased, suggesting that these mutations are associated with increased expression. By contrast, PTEN \( (P = 2.8 \times 10^{-19}) \) and ARID1A \( (P = 1.2 \times 10^{-6}) \) had high mutation rates in the remaining groups, but their expression was decreased, suggesting inactivating mutations in both genes. The copy-number high group also had decreased levels of phospho-AKT, consistent with downregulation of the AKT pathway. The copy-number low group had raised RAD50 expression, which is associated with DNA repair, explaining some of the differences between the copy-number high and low groups. The POLE group had high expression of ASNS and CCNB1, whereas the MSI tumours had both high phospho-AKT and low PTEN expression.

Unsupervised clustering of DNA methylation data generated from Illumina Infinium DNA methylation arrays revealed four unique subtypes (MC1–4) that support the four integrative clusters. A heavily methylated subtype (MC1) reminiscent of the CpG island methylator phenotype (CIMP) described in colon cancers and glioblastomas was associated with the MSI subtype and attributable to promoter hypermethylation of MLH1. A serous-like cluster (MC3) with minimal DNA methylation changes was composed primarily of serous tumours and some endometrioid tumours (Supplementary Fig. 7.1) and contained most of the copy-number high tumours.

Integrative clustering using the iCluster framework returned two major clusters split primarily on serous and endometrioid histology highlighting TP53 mutations, lack of PTEN mutation and encompassing almost exclusively copy-number high tumours (Supplementary Fig. 8.1). We developed a new clustering algorithm, called SuperCluster, to derive overall subtypes based on sample cluster memberships across all data types (Supplementary Fig. 9.1). SuperCluster identified four clusters that generally confirmed the contributions of individual platforms to the overall integrated clusters. No major batch effects were identified for any platform (Supplementary Methods 10).

**Structural aberrations**

To identify somatic chromosomal aberrations, we performed low-pass, paired-end, whole-genome sequencing on 106 tumours with matched normals. We found recurrent translocations involving genes in several pathways including WNT, EGFR–RAS–MAPK, PI(3)K, protein kinase A, retinoblastoma and apoptosis. The most frequent translocations (5 out of 106) involved a member of the BCL family (BCL2, BCL7A, BCL9 and BCL2L11). Four of these were confirmed by identification of the translocation junction point and two were also confirmed by high-throughput RNA sequencing (RNA-Seq). In all cases the translocations result in in-frame fusions and are predicted to result in activation or increased expression of the BCL family members (Supplementary Fig. 3.2). Translocations involving members of the BCL family leading to reduced apoptosis have been
used MEMo25 to identify gene networks with mutually exclusive recurrently mutated, homozygously deleted, and amplified genes, we targeted inhibitors. A small clinical trial of trastuzumab found no potential role for human epidermal growth factor receptor 2 (HER2)-expression in 25% of the serous or serous-like tumours, suggesting a (ref. 29).

Because of the high background mutation rate and small sample size, multiple platform data were integrated to identify recurrently altered mechanisms may be operative here.

**Pathway alterations**

Multiple platform data were integrated to identify recurrently altered pathways in the four endometrial cancer integrated subgroups. Because of the high background mutation rate and small sample size, we excluded the POLE subgroup from this analysis. Considering all recurrently mutated, homozygously deleted, and amplified genes, we used MEMo25 to identify gene networks with mutually exclusive alteration patterns in each subgroup. The most significant module was found in the copy-number low group and contained CTNNB1, KRAS and SOX17 (Fig. 4a). The very strong mutual exclusivity between mutations in these three genes suggests that alternative mechanisms activate WNT signalling in endometrioid endometrial cancer. Activating KRAS mutations have been shown to increase the stability of β-catenin via glycogen synthase kinase 3β (GSK-3β), leading to an alternative mechanism of β-catenin activation other than adenomatous polyposis coli degradation26. SOX17, which mediates protooncogenic degradation of β-catenin27,28, is mutated exclusively in the copy-number low group (8%) at recurrent positions (Ala96Gly and Ser403Ile) not previously described. Other genes with mutually exclusive alteration patterns in this module were FBXW7, FGFR2 and ERBB2 (ref. 29). ERBB2 was focally amplified with protein overexpression in 25% of the serous or serous-like tumours, suggesting a potential role for human epidermal growth factor receptor 2 (HER2)-targeted inhibitors. A small clinical trial of trastuzumab found no activity in endometrial carcinoma, but accrued few HER2 fluorescence in situ hybridization (FISH)-amplified serous carcinomas30.

PIK3CA and PIK3R1 mutations were frequent and showed a strong tendency for mutual exclusivity in all subgroups, but unlike other tumour types, they co-occurred with PTEN mutations in the MSI and copy-number low subgroups as previously reported3,9 (Fig. 4b). The copy-number high subgroup showed mutual exclusivity between alterations of all three genes. Overall, 93% of endometrioid tumours had mutations that suggested potential for targeted therapy with PI(3)K/AKT pathway inhibitors.

Consensus clustering of copy number, mRNA expression and pathway interaction data for 324 samples yielded five PARADIGM clusters with distinct pathway activation patterns31 (Fig. 4c and Supplementary Methods 11). PARADIGM cluster 1 had the lowest level of MYC pathway activation and highest level of WNT pathway activation, consistent with its composition of copy-number low cases having frequent CTNNB1 mutations. PARADIGM cluster 3 was composed predominantly of the copy-number high cases, with relatively high MYC/ MAX signalling but low oestrogen receptor/FOXA1 signalling and p53 activity. Only TP53 truncation and not nonsense mutations were implicated as loss-of-function mutations, suggesting different classes of p53 mutations may have distinct signalling consequences. PARADIGM cluster 5 was enriched for hormone receptor expression.

**Comparison to ovarian and breast cancers**

The clinical and pathologic features of uterine serous carcinoma and high-grade serous ovarian carcinoma (HGSOC) are quite similar. HGSOC shares many similar molecular features with basal-like breast carcinoma22. Focal SCNA patterns were similar between these three tumour subtypes and unsupervised clustering identified relatedness (Fig. 5a and Supplementary Fig. 12.1). Supervised analysis of transcriptome data sets showed high correlation between tumour subtypes (Supplementary Fig. 12.2). The MC3 DNA methylation subtype with minimal DNA methylation changes was also similar to basal-like breast and HGSOCs (Supplementary Fig. 12.3). A high frequency of TP53 mutations is shared across these tumour subtypes (uterine serous, 91%; HGSOC, 96%; basal-like breast, 84%33,34, as is the very low frequency of PTEN mutations (uterine serous, 2%; HGSOC, 1%; basal-like breast, 1%). Differences included a higher frequency of FBXW7, PPP2R1A and PIK3CA mutations in uterine serous compared to basal-like breast and HGSOCs (Fig. 5b). We showed that uterine serous carcinomas share many molecular features with both HGSOCs and basal-like breast carcinomas, despite more frequent mutations, suggesting new opportunities for overlapping treatment paradigms.

**Discussion**

This integrated genomic and proteomic analysis of 373 endometrial cancers provides insights into disease biology and diagnostic classification that could have immediate therapeutic application. Our analysis identified four new groups of tumours based on integrated genomic data, including a novel POLE subtype in ~10% of endometrioid tumours. Ultrahigh somatic mutation frequency, MSS, and common, newly identified hotspot mutations in the exonuclease domain of POLE characterize this subtype. SCNAs add a layer of resolution, revealing that most endometrioid tumours have few SCNAs, most serous and serous-like tumours exhibit extensive SCNAs, and the extent of SCNA roughly correlates with progression-free survival.

Endometrial cancer has more frequent mutations in the PI(3)K/AKT pathway than any other tumour type studied by The Cancer Genome Atlas (TCGA) so far. Endometrioid endometrial carcinomas share many characteristics with colorectal carcinoma including a high frequency of MSI (40% and 11%, respectively), POLE mutations (7% and 3%, respectively) leading to ultrahigh mutation rates, and frequent activation of WNT/CTNNB1 signalling; yet endometrial carcinomas have novel exclusivity of KRAS and CTNNB1 mutations and a distinct mechanism of pathway activation. Uterine serous carcinomas share many similar characteristics with basal-like breast and HGSOCs; three tumour types with high-frequency non-silent TP53 mutations and extensive SCNA. However, the high frequency of PIK3CA, FBXW7, PPP2R1A and ARID1A mutations in uterine serous carcinomas are not found in basal-like breast and HGSOCs. The frequency of mutations in PIK3CA, FBXW7 and PPP2R1A was ~30% higher than in a recently

---

**Figure 3** Gene expression across integrated subtypes in endometrial carcinomas. a, Supervised analysis of ~1,500 genes significantly associated with integrated subtypes. b, Heat map of protein expression clusters, supervised by integrated subtypes. Samples are in columns; genes or proteins are in rows.
reported study of 76 uterine serous carcinomas\textsuperscript{1}, but similar to another study\textsuperscript{12}. Uterine serous carcinomas have ERBB2 amplification in 27% of tumours and PIK3CA mutations in 42%, which provide translational opportunities for targeted therapeutics.

Early stage type I endometrioid tumours are often treated with adjuvant radiotherapy, whereas similarly staged type II serous tumours are treated with chemotherapy. High-grade serous and endometrioid endometrial carcinomas are difficult to subtype correctly, and intra-observer concordance among speciality pathologists is low\textsuperscript{7,34–36}. Our molecular characterization data demonstrate that ~25% of tumours classified as high-grade endometrioid by pathologists have a molecular phenotype similar to uterine serous carcinomas, including frequent TP53 mutations and extensive SCNA. The compelling similarities between this subset of endometrioid tumours and uterine serous carcinomas suggest that genomic-based classification may lead to improved management of these patients. Clinicians should carefully consider treating copy-number-altered endometrioid patients with chemotherapy rather than adjuvant radiotherapy and formally test such hypotheses in prospective clinical trials. Furthermore, the marked molecular differences between endometrioid and serous-like tumours suggest that these tumours warrant separate clinical trials to develop the independent treatment paradigms that have improved outcomes in other tumour types, such as breast cancer.

**METHODS SUMMARY**

Biopsicemis were obtained from 373 patients after Institutional Review Board-approved consents. DNA and RNA were co-isolated using a modified AllPrep kit (Qiagen). We used Affymetrix SNP 6.0 microarrays to detect SCNAS in 363 samples and GISTIC analysis to identify recurrent events\textsuperscript{37}. The exomes of 248 samples and GISTIC analysis to identify recurrent events\textsuperscript{37}. The exomes of 248 samples were sequenced to a read-depth of least 20x. We performed low-pass whole-genome sequencing on 107 tumours to a mean depth of \times 6. Consensus clustering was used to analyse miRNA, miRNA, RPPA and methylation data with methods previously described\textsuperscript{49, 50}. Integrated cross-platform analyses were performed using MEMo, iTCluster and PARADIGM\textsuperscript{23, 31}.

Received 10 December 2012; accepted 21 March 2013.


©2013 Macmillan Publishers Limited. All rights reserved


©2013 Macmillan Publishers Limited. All rights reserved
Lawrence1; Institute for Systems Biology Sheila M. Reynolds1,2; Ilya Shmulevich2; Memorial Sloan-Kettering Cancer Center B. Arman Aksoy2; Yevgeniy Antipin2; Giovanni Ciriello3; Gideon Dresner2; Tianjiong Gao2; Benjamin Glass4; Anders Jacobs6; Boris Ladanyi2; Boris Reva2; Chris Sanders2; Rolen Sinha2; Shun-Sun Sumre3; Bary S. Taylor2; Ethan Cerami2; Nili Weisshold2; Nikolaus Schultz4; Ronglin Shen5; University of California, Santa Cruz/Buck Institute Stephen Ben2; Beth Goldstein2; David Haussler2; Sam Ng2; Christopher Szeto2; Joshua Stuart2; Christopher C. Vardiman3; Cancer Genome Project Center Wei Jiang3; Badii Anna3; Bradley M. Broom3; Ted D. Casetasen3; Zhenlin Ju3; Hang Liang3; Guoyan Liu3,4; Yiling Lu3; Anna K. Unruh3; Chris Wakefield3; John N. Weinstein3; Nianxiang Zhang3; Yexiu Liu3,5; Russell Broadus6; Rehan Akbani3; Gordon B. Mills5.

Bioinformatic core resource: Nationwide Children’s Hospital Christopher Adams6; Thomas Barr7; Aaron D. Black8; Jay Bowen9; John Deardurff9; Jessica Frick9; Julie M. Gastier-Foster10; Russell Broaddus11; Thomas Grossman12; Hollie A. Harper13; Melissa Hart-Kothan13; Carmen Helsel13; Aaron Hobensack13; Harkness Kuck14; Kelley Kneale15; Kristen M. Leraas15; Tara M. Lichtenberg35; Cynthia McAllister35; Robert E. Pyatt35; Nilsa C. Ramires35; Teresa R. Taber35; Nathan Vanhoose35; Peter White35; Lisa Wise35; Erik Zmuda35.

Biases in cancer: California Cancer Research Park Giovanni Ciriello3; Gi d e o n D r e s d n e r24; Jianjiong Gao24; Benjamin Gross24; Anders Dowdy49; Boris Winterhoff49; Marc T. Goodman58;59; A. Gordon Robertson3; Ram e e n Ozenberger70; Heidi J. Sofia70; Zhenlin Ju3; Han Liang3; Guoyan Liu3; Yiling Lu3; Anna K. Unruh3; Chris Wakefield3; John N. Weinstein3; Nianxiang Zhang3; Yexiu Liu3; Russell Broadus6; Rehan Akbani3; Gordon B. Mills5.

Women’s Hospital, Boston, Massachusetts 02115, USA.5Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA.6Department of Genetics, Harvard Medical School, Boston, Massachusetts 02215, USA.10Center for Biomedical Informatics, Harvard Medical School, Boston, Massachusetts 02115, USA.11Institute for Applied Cancer Science, Department of Genomic Medicine, University of Washington, Seattle, Washington 98195, USA.12Boston Children’s Hospital Program, Boston Children’s Hospital, Boston, Massachusetts 02215, USA.13Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.14Institute for Pharmacogenetics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.15Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.16Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.17Research Computing Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.18Department of Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231, USA.19University of Southern California Epigenome Center, University of Southern California, Los Angeles, California 90089, USA.20Institute for Systems Biology, Seattle, Washington, USA.21Comprehensive Cancer Center, New York, New York 10065, USA.22Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.23Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94143, USA.24The Cancer Genome Project, Children’s Hospital, Boston, MA 02115, USA.25Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.26Department of Biomolecular Engineering and Center for Biomolecular Science and Engineering, University of California Santa Cruz, Santa Cruz, California 95064, USA.27Department of Bioinformatics and Cancer Informatics, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.28Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.29Department of Genetics, The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio 43210, USA.30The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.31Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.32Tampere University of Technology Korkeakoulunkatu 10, Tampere, Finland, Finland 33014, USA.33A. Gordon Robertson3; Itai Pashtan1,4,5; Abramov53; Martin L. Ferguson69; John A. Demchok67,68; Cureline; noodles24, Barry S. Taylor26, Ethan Cerami24, Nils Weinhold24, Nikolaus Schultz24, Andrew D. Cherniack1, Erin Curley48, Johanna Gardner48, David Mallery48, Robert N. N. Blokhin Russian Cancer Research Center, Moscow, Russia.34Laboratory Medicine, The University of British Columbia, Vancouver, British Columbia V6H 3M5, Canada.35University of California, Santa Cruz/Buck Institute, Santa Cruz, California 95064, USA.36Department of Clinical Medicine, Haukeland University Hospital, Bergen, Norway.37Department of Pathology, University of North Carolina, Chapel Hill, North Carolina 27599, USA.38University of North Carolina, Chapel Hill, North Carolina 27599, USA.39OvCaRe British Columbia, British Columbia Cancer Agency, Vancouver, British Columbia V5Z 4E6, Canada.40Department of Pathology & Laboratory Medicine, The University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada.41Women’s Cancer Program at the Tisch Cancer Institute for Systems Biology, Seattle, Washington, USA.42Helen F Graham Cancer Center at Christiana Care, Newark, Delaware 19713, USA.43Cureline, Inc., South San Francisco, California 94080, USA.44Duke University Medical Center, Durham, North Carolina 27705, USA.45University of California, Los Angeles, Los Angeles, California 90095, USA.46University of California Medical Center, Irvine, Orange California 92868, USA.47GOG Tissue Bank, The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio 43210, USA.48International Genomics Consortium, Phoenix, Arizona 85004, USA.49Department of OB Gyn, Division of Gynecologic Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA.50Department of Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA.51Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.52Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.53Tisch Cancer Institute, New York, New York 10065, USA.54Department of Biostatistics and Informatics, Mayo Clinic, Rochester, Minnesota 55905, USA.55Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas 77030, USA.56The Cancer Genome Atlas Program Office, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.57Department of Pathology, University of North Carolina, Chapel Hill, North Carolina 27599, USA.58University of Washington, Seattle, Washington, USA.59University of California, Irvine, Orange, California 92868, USA.60University of California, Irvine, Orange, California 92868, USA.61Washington University School of Medicine, St Louis, Missouri 63110, USA.62SRA International, Fairfax, Virginia 22033, USA.63Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.64Institute of Pharmacy and Biomedical Informatics, Queensland University of Technology, Brisbane 4059, Australia.65Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota 55905, USA.66Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas 77030, USA.67The Cancer Genome Atlas Program Office, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.68Cermons, LLC, Atlanta, Georgia 30366, USA.69MLF Consulting, Arlington, Maryland 02474, USA.70National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Erratum: Integrated genomic characterization of endometrial carcinoma

The Cancer Genome Atlas Research Network

In the ‘Results’ section of this Article, the range in the sentence “The median follow-up of the cohort was 32 months (range, 1–19 months); 21% of the patients have recurred, and 11% have died.” should have been 1–195 months. This error has been corrected in the HTML and PDF versions of the paper.